Annual Cash & Cash Equivalents
$391.56 M
-$158.35 M-28.79%
December 31, 2023
Summary
- As of February 7, 2025, RXRX annual cash & cash equivalents is $391.56 million, with the most recent change of -$158.35 million (-28.79%) on December 31, 2023.
- During the last 3 years, RXRX annual cash & cash equivalents has risen by +$129.44 million (+49.38%).
- RXRX annual cash & cash equivalents is now -28.79% below its all-time high of $549.91 million, reached on December 31, 2022.
Performance
RXRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$427.65 M
-$46.69 M-9.84%
September 30, 2024
Summary
- As of February 7, 2025, RXRX quarterly cash and cash equivalents is $427.65 million, with the most recent change of -$46.69 million (-9.84%) on September 30, 2024.
- Over the past year, RXRX quarterly cash and cash equivalents has increased by +$131.32 million (+44.32%).
- RXRX quarterly cash and cash equivalents is now -32.41% below its all-time high of $632.74 million, reached on June 30, 2021.
Performance
RXRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RXRX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -28.8% | +44.3% |
| 3 y3 years | +49.4% | -22.2% |
| 5 y5 years | +460.3% | -22.2% |
RXRX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -28.8% | +37.3% | -22.2% | +50.0% |
| 5 y | 5-year | -28.8% | +460.3% | -32.4% | +99.8% |
| alltime | all time | -28.8% | +460.3% | -32.4% | +99.8% |
Recursion Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $427.65 M(-9.8%) |
| Jun 2024 | - | $474.34 M(+60.1%) |
| Mar 2024 | - | $296.33 M(-24.3%) |
| Dec 2023 | $391.56 M(-28.8%) | $391.56 M(+1.1%) |
| Sep 2023 | - | $387.32 M(-4.6%) |
| Jun 2023 | - | $405.87 M(-14.2%) |
| Mar 2023 | - | $473.14 M(-14.0%) |
| Dec 2022 | $549.91 M | $549.91 M(+21.0%) |
| Sep 2022 | - | $454.65 M(+0.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $453.88 M(-10.6%) |
| Mar 2022 | - | $507.89 M(+78.1%) |
| Dec 2021 | $285.12 M(+8.8%) | $285.12 M(-27.8%) |
| Sep 2021 | - | $394.72 M(-37.6%) |
| Jun 2021 | - | $632.74 M(+195.6%) |
| Mar 2021 | - | $214.09 M(-18.3%) |
| Dec 2020 | $262.13 M(+275.1%) | - |
| Dec 2020 | - | $262.13 M |
| Dec 2019 | $69.88 M | - |
FAQ
- What is Recursion Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Recursion Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Recursion Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of RXRX is $391.56 M
What is the all time high annual cash & cash equivalents for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual cash & cash equivalents is $549.91 M
What is Recursion Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, RXRX annual cash & cash equivalents has changed by -$158.35 M (-28.79%)
What is Recursion Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RXRX is $427.65 M
What is the all time high quarterly cash and cash equivalents for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly cash and cash equivalents is $632.74 M
What is Recursion Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, RXRX quarterly cash and cash equivalents has changed by +$131.32 M (+44.32%)